|
|||||
|
|
| 托珠单抗治疗全身型幼年特发性关节炎的疗效和安全性 | |
| 引用本文： | 李艳蝶. 托珠单抗治疗全身型幼年特发性关节炎的疗效和安全性[J]. 国际儿科学杂志, 2017, 44(2). DOI: 10.3760/cma.j.issn.1673-4408.2017.02.007 |
| 作者姓名： | 李艳蝶 |
| 作者单位： | 浙江大学医学院附属儿童医院风湿免疫变态反应科,杭州,310003 |
| 摘 要： | 幼年特发性关节炎(juvenile idiopathic arthritis,JIA)是最常见的儿童风湿性疾病之一.全身型幼年特发性关节炎(systemic juvenile idiopathic arthritis,SJIA)是JIA的一个亚型,其发病机制可能有别于其他亚型.已有研究表明,IL-6、IL-18、IFN-γ而非TNF-α在SJIA中起主要作用.传统的生物制剂如TNF拮抗剂对SJIA疗效有限.托珠单抗(tocilizumab,TCZ)是一种人源化抗人白细胞介素-6受体(IL-6R)的单克隆抗体,通过抑制IL-6与跨膜型IL-6R或可溶型IL-6R的结合,阻断IL-6介导的炎性反应和关节破坏.该文就TCZ治疗SJIA的疗效和安全性研究进展作一综述. |
| 关 键 词： | 托珠单抗 幼年特发性关节炎全身型 白细胞介素-6 疗效 安全性 |
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis |
|
| Li Yandie. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis[J]. International Journal of Pediatrics, 2017, 44(2). DOI: 10.3760/cma.j.issn.1673-4408.2017.02.007 | |
| Authors: | Li Yandie |
| Abstract: | Juvenile idiopathic arthritis (JIA)is one of the most common chronic rheumatic diseases in childhood.Systemic juvenile idiopathic arthritis(SJIA) is a subtype of JIA,which may be different from other subtypes.As shown in studies,interleukin-6 (IL-6),IL-18,IFN-γ,may instead of TNF-α,play an important role in SJIA.Traditional biological agents such as TNF antagonists have limited effect in the patients with SJIA.Tocilizumab(TCZ),a humanized anti-IL-6 receptor monoclonal antibody,inhibits the binding of IL-6 with transmembrane IL-6R or soluble IL-6R,blocking the IL-6 mediated inflammation and joint destruction.This article reviews the efficacy and safety of TCZ in patients with SJIA. |
| Keywords: | Tocilizumab Systemic juvenile idiopathic arthritis Interleukin-6 Efficacy Safety |
| 本文献已被 万方数据 等数据库收录！ | |